NCT07225842 The Bridging Antiplatelet Therapy With Cangrelor 2 Study
| NCT ID | NCT07225842 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Florida |
| Condition | Coronary Arterial Disease (CAD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-18 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2026-02-18 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.
Eligibility Criteria
Inclusion Criteria: 1. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care. 2. Age ≥18 years 3. Provide written informed consent. Exclusion Criteria: 1. Need for urgent surgery 2. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females 3. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours. 4. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose
Contact & Investigator
Dominick J Angiolillo, MD, PhD
STUDY CHAIR
University of Florida College of Medicine - Jacksonville
Frequently Asked Questions
Who can join the NCT07225842 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Arterial Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07225842 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07225842 currently recruiting?
Yes, NCT07225842 is actively recruiting participants. Contact the research team at Luis.Ortega@jax.ufl.edu for enrollment information.
Where is the NCT07225842 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT07225842 clinical trial?
NCT07225842 is sponsored by University of Florida. The principal investigator is Dominick J Angiolillo, MD, PhD at University of Florida College of Medicine - Jacksonville. The trial plans to enroll 50 participants.